Treats hypertension. ANDA 203828, held by Indchemie Health Specialities. Nebivolol Hydrochloride.
As of Nov 21, 2026, ANDA 203828 (Nebivolol Hydrochloride), held by Indchemie Health Specialities, was first approved by FDA on Jul 29, 2015, with 3 approved supplements and 0 published complete response letters.
Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 2015 | Original application | Approved | None posted |
| Nebivolol HydrochlorideEQ 2.5MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Nebivolol HydrochlorideEQ 5MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Nebivolol HydrochlorideEQ 10MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Nebivolol HydrochlorideEQ 20MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Aug 27, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 25, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 19, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 29, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters